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Modification of the loops in the ligand-binding
site turns avidin into a steroid-binding protein
Tiina A Riihimäki1, Soili Hiltunen1, Martina Rangl2, Henri R Nordlund1, Juha AE Määttä1, Andreas Ebner2,
Peter Hinterdorfer2, Markku S Kulomaa1, Kristiina Takkinen3 and Vesa P Hytönen1*
Abstract
Background: Engineered proteins, with non-immunoglobulin scaffolds, have become an important alternative to
antibodies in many biotechnical and therapeutic applications. When compared to antibodies, tailored proteins may
provide advantageous properties such as a smaller size or a more stable structure.
Results: Avidin is a widely used protein in biomedicine and biotechnology. To tailor the binding properties of
avidin, we have designed a sequence-randomized avidin library with mutagenesis focused at the loop area of the
binding site. Selection from the generated library led to the isolation of a steroid-binding avidin mutant (sbAvd-1)
showing micromolar affinity towards testosterone (Kd ~ 9 μM). Furthermore, a gene library based on the sbAvd-1
gene was created by randomizing the loop area between b-strands 3 and 4. Phage display selection from this
library led to the isolation of a steroid-binding protein with significantly decreased biotin binding affinity compared
to sbAvd-1. Importantly, differential scanning calorimetry and analytical gel-filtration revealed that the high stability
and the tetrameric structure were preserved in these engineered avidins.
Conclusions: The high stability and structural properties of avidin make it an attractive molecule for the
engineering of novel receptors. This methodology may allow the use of avidin as a universal scaffold in the
development of novel receptors for small molecules.
Keywords: protein engineering, avidin scaffold, phage display, steroid hormone, testosterone
Background
Antibodies are the most widely used biomolecules for
therapeutic, diagnostic and research applications,
because they can be generated against virtually any
molecule using protein engineering techniques (for a
review see [1]). However, antibodies have certain funda-
mental disadvantages such as the complex architecture
of their antigen-binding site, low stability, and a rather
large size [2-5]. Moreover, the production of full-size
antibodies is relatively expensive [6]. To overcome these
limitations and to improve therapeutic antibodies, anti-
bodies have been extensively engineered [7]. For exam-
ple the size of the antibody molecule has been reduced
by producing single-domain antigen-binding derivatives
[8]. In addition to extensive antibody engineering, a
versatile repertoire of tailored biomolecules from non-
immunoglobulin protein scaffolds have been generated
[4,9,10]. Anticalins, derived from the lipocalin fold, are a
good example of engineered proteins [11]. The b-barrel
structure of lipocalins is thermostable and robust and
serves as an excellent scaffold for engineering novel
receptors. They have been modified to bind novel
ligands, such as fluorescein and digoxigenin, with affi-
nities comparable with antibodies [12].
Chicken avidin (Avd), known for its extremely high
affinity towards the water-soluble vitamin H, D-biotin,
has been widely used in life science research applica-
tions [13]. Aside from biotin, Avd also binds dyes and
peptides, which share no significant structural similarity
with biotin [14,15]. Avd provides an attractive robust
scaffold for the development of novel receptors, and
Avd has many advantageous properties such as high
chemical and thermal stability, a deep ligand binding
site optimized for the binding of small molecules, and
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an oligomeric nature enabling signal amplification.
Moreover, the structure of Avd is well characterized
[16,17] and numerous engineered forms of Avd have
been described [18]. Engineered Avd forms, in which
the two pairs of the binding sites (dual-chain Avd)
[19-21] or all four binding sites (single-chain Avd) [22]
can be independently manipulated, have been developed.
In the present study Avd was modified to bind steroid
hormones. Avd mutant sbAvd-1, which was captured
using the phage display selection [23], has a micromolar
affinity to testosterone. The steroid-binding protein
sbAvd-1 was characterized and further engineered to
decrease cross-reactivity towards other molecules, espe-
cially towards Avd’s natural ligand biotin. The resulting
sbAvd-2 mutant with a modified loop between b-strands
3 and 4 was found to prefer steroid hormones over bio-
tin in ligand binding.
Results
Functional display of Avd protein on the M13 phage
Avd was displayed on the surface of the M13 phage as a
fusion with the C-terminal region of the minor coat
protein pIII. Two different strategies for displaying the
Avd scaffold in the active form on the M13 phage were
evaluated. In the first display construct, Avd was pro-
duced solely as a fusion with pIII (Avd-pIII; Figure 1A),
whereas in the Avd/Avd-pIII display construct, free Avd
subunits were produced in addition to the pIII fusion
(Figure 1B).
The size and oligomeric state of the Avd-pIII fusions
were analyzed by SDS-PAGE and by western blot. Poly-
clonal anti-Avd (Figure 2A) indicated expression of both
the Avd-pIII fusion (upper arrow, ~38 kDa) and the free
Avd (lower arrow, ~15 kDa). The production of free
subunits should enhance the functional assembly of the
tetrameric Avd scaffold, especially if membrane anchor-
ing of Avd by the pIII fusion partner has a negative
effect on the oligomerization of Avd subunits. This
strategy mimics the generally used amber-stop codon
technique, in which free subunits are produced by the
read-through of amber stop codon by the tRNA. We
assume that the oligomerization of Avd, secreted by the
pelB signal sequence, occurs in the periplasmic space of
E. coli, allowing the display of functional Avd on the
phage, as is the case for the display of the antibody Fab
fragment, which requires folding of the heavy and light
chains for the assembly of a functional antibody mole-
cule [24].
A portion of the Avd-pIII fusion was partially proteo-
lytically cleaved, as can be seen from the blot analyzed
with the anti-pIII monoclonal antibody (Figure 2B, ~35
kDa band). Because Avd display constructs designed in
this study were based on the monovalent display mode
(3 + 3), the intact pIII (migrating at ~58 kDa) expressed
from the helper phage was also detected from the blot
(Figure 2B, uppermost arrow).
Avd-displaying phages were functional because they
bound specifically to the biotin-coated surfaces, and
phages were efficiently amplified even after several pan-
ning rounds. Moreover, phagemid DNA with the Avd
display expression unit, which was confirmed by the
restriction enzyme digestion analysis, was stable during
the panning rounds (data not shown).
To analyze the functionality of phages, the mixture of
amplified Avd and Avd mutant N118M phages were
screened by panning against 4-hydroxyazobenzene-2-
carboxylic acid (HABA). As determined in our previous
study, the biotin binding affinity of the Avd mutant
N118M was reduced ~1,000,000-fold (Kd = 4.2 × 10
-9
M) and HABA-affinity was increased ~1.5-fold (Kd = 5.2
× 10-6 M) compared to wtAvd [25] (Additional file 1).
During the panning procedure a clear enrichment of
Figure 1 Schematic presentation of the Avd display expression
constructs. (A) The phagemid constructs for Avd and Avd(N118M)
display, in which Avd protein is produced solely as a fusion with
pIII. (B) The phagemid constructs for Avd/Avd-pIII and Avd(N118M)/
Avd(N118M)-pIII display, in which the pelB signal sequence is used
for secretion of the Avd-pIII fusions and the free Avd. The cloning
sites used are shown by vertical arrows.
Figure 2 Immunoblot analysis of Avd phages with anti-Avd
and anti-pIII antibodies. (A) The location of the Avd-pIII fusion
protein recognized by anti-Avd is indicated by the upper
arrowhead. The theoretical mass of the Avd-pIII fusion protein is 38
kDa. The produced free Avd (~14 kDa) is indicated with the lower
arrowhead. (B) From the immunoblot analyzed with anti-pIII
antibody the full-length pIII expressed from the helper phage
(VCSM13) can be seen migrating at ~60 kDa (the upper arrowhead).
The Avd-pIII fusion is indicated by the middle arrowhead. In
addition, some proteolytically truncated Avd-pIII forms were
detected (~33 kDa; lower arrowhead). Lane 1: Avd-pIII phage; lane 2:
Avd(N118M)-pIII phage; lane 3: Avd/Avd-pIII phage; lane 4: Avd
(N118M)/Avd(N118M)-pIII phage. The molecular weights of standard
proteins are shown as kilodaltons on the left side of each blot.
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Avd(N118M) phages over wt Avd phages was detected,
which was an indication of the high selectivity of the
produced phages. After only three rounds of selection
phages displaying the Avd mutant N118M outcompeted
the wtAvd phage population (Additional file 2).
Capture of a steroid-binding avidin
The loops adjacent to the ligand-binding site were
selected for randomization [16]. First we created a
library (Avd L1,2 library) in which residues N12, D13,
L14, G15, and S16 were randomized. These amino acids
form a loop between b-strands 1 and 2 (Figure 3).
Codon NNN was used for randomization, and therefore,
all 20 different amino acids were present, including all
stop codons. The Avd L1,2 library was ligated into a
phagemid as a sole fusion with the C-terminal portion
of pIII. Based on sequencing results and transformation
efficiency, the Avd L1,2 library was found to consist of
approximately 1 × 105 individual members. When a
stretch of five amino acid residues is completely rando-
mized, the theoretical library size is 3.2 × 106.
In the panning experiments Avd L1,2 loop library
phages were introduced onto a testosterone-coated sur-
face. The phage genomes carrying the mutated cDNA
were found to be stable during the selection. A clear
enrichment of sequences in the randomized loop area
was observed, indicating the success of the selection
conditions. Interestingly, we detected N12 as being a
highly conserved amino acid residue among the
enriched pool of proteins. An Avd variant, named
sbAvd-1, that carried the sequence N12, R13, M14, N15,
H16 was selected for further analysis.
The specificity of sbAvd-1 can be tuned by additional
mutations in the loop between b-strands 3 and 4
To further lower the biotin-binding affinity and to
decrease the cross-reactivity of steroid-binding Avd, a
library (sbAvd-1 L3,4) was generated in which the loop
area between b-strands 3 and 4 was randomized
(Figure 3). The loop between b-strands 3 and 4 is
highly important for biotin binding of Avd because
this loop ‘locks’ biotin into the binding site. In this
process, three amino acid residues in the loop form
direct interactions with biotin [16]. In the library four
amino acids (T35, A36, V37 and, T38) were rando-
mized using the NNY codon. The use of this codon
covers 14 of the 20 naturally occurring amino acids
while eliminating all of the stop codons. The library
consisted of approximately 1.4 × 106 individual mem-
bers, when calculated from the sequencing results and
transformation efficiency, which exceeds the theoretical
size of the library calculated based on the possible
combinations of amino acid residues (3.8 × 104).
Binders from the sbAvd-1 L3,4 library were selected
by phage display panning against a testosterone sur-
face. In every panning round washes were adjusted
according to the number of output colonies. The
quality of the phage genomes carrying the mutated
cDNA was evaluated by DNA sequencing at various
stages during selection. A combination of acid and tes-
tosterone was used for elution. The selected sbAvd-1
phage clones were evaluated by microplate analysis
using BSA-testosterone as a target ligand and utilizing
M13-antibody to determine the amount of bound
phages. The sbAvd-1 variant that showed the highest
binding activity in the microplate assay (data not
shown) had the sequence A35, T36, V37, N38. This
mutant, named sbAvd-2 was selected for comparative
analysis with sbAvd-1.
Production and purification of Avd mutants
Proteins were produced in soluble form in the E. coli
strain BL21-AI using N-terminal OmpA bacterial
secretion signal from Bordetella avium [26]. Proteins
were purified by Ni-NTA affinity chromatography
that yielded ~2 mg/L pure protein. According to gel-
filtration analysis, in solution, both sbAvd-1 (51 kDa)
and sbAvd-2 (53 kDa) showed tetrameric state (Addi-
tional file 3) similar to that of wtAvd (Avd expressed
in E. coli 53 kDa, chicken Avd 60 kDa [26]). The
slight decrease in molecular weight of Avd expressed
in bacteria can be explained by the lack of
glycosylation.
Figure 3 Three-dimensional structure of wtAvd with the loops
chosen for random mutagenesis marked. One subunit of
tetrameric wtAvd with bound biotin (PDB: 2AVI) [16] is shown in the
figure. The randomized amino acid residues are N12, D13, L14, G15,
and S16 (shown in blue) in the loop between b-strands 1 and 2,
and T35, A36, V37, and T38 (shown in purple) in the loop between
b-strands 3 and 4.
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Determination of ligand-binding specificity of Avd forms
by microplate assay
The binding specificity of proteins was analyzed by micro-
plate assay, in which a set of different small molecules
were used as a target molecules (Figure 4A). WtAvd was
used as a negative control, and we detected no affinity
towards the ligands except biotin. Importantly, sbAvd-1
and sbAvd-2 did not bind the proteins used as carriers for
small molecules (bovine serum albumin (BSA) and human
serum albumin (HSA)). However, these modified Avds
showed clear binding to testosterone and progesterone.
The binding to the surface-immobilized ligands
was inhibited by pre-incubating the proteins with 10
μM D-biotin (Figure 4B). Free biotin significantly inhib-
ited the binding of sbAvd-1 to steroids, indicating nota-
ble affinity towards biotin. However, in the case of
sbAvd-2 the binding of testosterone and progesterone
was not affected by biotin, showing a clear decrease in
biotin-binding affinity.
Biosensor analyses of steroid-binding Avds
The kinetic constants of testosterone- and biotin-bind-
ing to steroid-binding proteins were determined with
surface plasmon resonance (SPR) analysis. The purified
sbAvd-1 and sbAvd-2 bound to a testosterone-BSA-
coated sensor chip with similar affinities (Table 1),
whereas wtAvd showed no binding to the testosterone
surface. Furthermore, testosterone-binding was inhibited
with varying testosterone concentrations (0.75-50 μM,
data not shown). In the case of sbAvd-1, the 50% inhibi-
tion was achieved between 5-10 μM testosterone, which
is consistent with the determined testosterone surface
binding affinity. Interestingly, the 50% inhibition was
already achieved in 750 nM testosterone concentration
in the sbAvd-2 measurements. This result suggests a
much higher binding affinity towards free testosterone
than that measured towards surface-immobilized
testosterone.
The biotin binding of the steroid-binding proteins was
analyzed by the biotin-coated sensor chip. The compari-
son of sbAvd-1 and sbAvd-2 revealed that the biotin-
binding affinity decreased almost 500-fold due to the
modification of the loop between b-strands 3 and 4
(Table 1). This result appears to be consistent with the
previous study in which mutation of T35A alone
decreased the biotin-binding affinity of wtAvd approxi-
mately 200-fold [20].
The specificity of the steroid-binding was analyzed
by binding competition using the following
steroids: testosterone, dehydroepiandrosterone sulfate
(DHEAS), androstenedione, estradiol, and dihydrotes-
tosterone (DHT). In addition, the binding to the sur-
face was also competed for by biotin. SbAvd-1 was
found to be cross-reactive with androgens highly simi-
lar to testosterone (DHEAS and androstenedione), and
had noticeable affinity towards biotin (Figure 5A).
Interestingly, DHT showed less efficient inhibition
compared to testosterone, suggesting lower binding
affinity towards this steroid form. The binding of
sbAvd-2 to testosterone was found to be most effi-
ciently inhibited by testosterone and DHEAS (Figure
5B), whereas the inhibition caused by biotin was
clearly weaker than that in the case of sbAvd-1. This
result is consistent with the microplate analysis results
and with the binding kinetic constants determined
with SPR analysis.
Figure 4 Determination of ligand-binding specificity of sbAvd-
1 and sbAvd-2 proteins by microplate analysis. The binding of
sbAvd-1 and sbAvd-2 to a set of different small ligands was
detected using polyclonal anti-avidin antibody as a probe (A) and
the effect of free biotin (10 μM) to ligand-binding was analyzed (B).
Abbreviations used in the figure: PBS, Phosphate buffered saline;
HSA, human serum albumin; PRO, HSA-conjugated progesterone;
HYD, HSA-conjugated hydrocortisone; TES, HSA-conjugated
testosterone; CHO, HSA-conjugated cholic acid; TES-B, BSA-
conjugated testosterone; BTN, BSA-conjugated D-biotin; BSA, bovine
serum albumin.
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Interaction analysis of steroid-binding Avds by MRFS
Molecular recognition force spectroscopy (MRFS) [27]
was used to study the interaction between sbAvds and
testosterone on a single molecule level. An atomic force
microscopy (AFM) tip was functionalized with a single
testosterone molecule [28] and repeatedly approached
and retracted from the sbAvd-1- or sbAvd-2-coated sur-
face (Figure 6A). The binding forces were measured in
force-distance cycles, whereby the deflection (force) of
the cantilever was recorded as a function of the tip-sam-
ple distance. For evaluation, 1,000 force-distance cycles
were recorded, and probability density functions (pdf)
were generated from the detected interaction forces
[29]. The tip-tethered testosterone was found to form a
complex with the sbAvds; the retraction led to a
downward bending of the cantilever until a particular
force was reached resulting in the rupture of the bond
between testosterone and sbAvd (Figure 6B and 6C).
The most probable unbinding force [29] was found to
be similar for both of the testosterone-sbAvd complexes:
40 pN at a constant pulling velocity of 600 nm/s. From
1,000 recorded force-distance cycles, sbAvd-1 showed
183 detected interactions and sbAvd-2 showed 215
events.
To prove the specificity of the measured interactions,
control experiments were performed. For these experi-
ments, free testosterone was injected into the measuring
solution to preoccupy the binding sites of the steroid-
binding protein immobilized on the surface. The retrac-
tion curve identical to the approaching curve was
Table 1 Kinetic parameters and the determined thermostability of sbAvds
Protein Ligand SPR DSC
ka (1/Ms) kd (1/s) KD (M) Tm (°C) ΔTm (°C) ΔH ×10
4 (cal/mol)
wtAvd - - - - 85.5 - 5.4
wtAvd Btn n.d. n.d. n.d. 123.2 37.7 12.8
wtAvd Tes - - no binding 86.2 0.7 5.6
sbAvd-1 - - - - 80.6 - 5.2
sbAvd-1 Btn 4.2 × 105 5.6 × 10-4 1.4 × 10-9 83.2 2.6 6.4
sbAvd-1 Tes 1.0 × 103 9.5 × 10-3 9.0 × 10-6 81.5 0.9 5.7
sbAvd-2 - - - - 82.5 - 4.6
sbAvd-2 Btn 1.0 × 103 6.8 × 10-4 6.6 × 10-7 83.0 0.5 4.2
sbAvd-2 Tes 813 8.5 × 10-3 1.1 × 10-5 83.1 0.6 4.8
The kinetic parameters determined by SPR analysis. The biotin binding affinity of avidin is too high to be determined by SPR. The transition midpoint of thermal
unfolding (Tm) and the calorimetric heat of unfolding were determined by DSC. Delta Tm represents the increase of Tm in the presence of 50 μM ligand.
Figure 5 Inhibition analysis of sbAvd-1 and sbAvd-2 proteins by the SPR method. The binding of the sbAvd-1 and the sbAvd-2 to a CM5
sensor chip functionalized with testosterone-BSA was measured in the presence of 50 μM inhibitors. (A) The binding of the sbAvd-1 protein was
totally inhibited by dehydroepiandrosterone, androstenedione, and biotin. (B) The binding of the sbAvd-2 protein was totally inhibited by
dehydroepiandrosterone or testosterone, but not biotin. This result is due to the markedly decreased affinity of the protein towards biotin.
Samples: Protein sample, green; protein with estradiol, dark blue; protein with DHT, olive; protein with testosterone, black; protein with DHEAS,
blue; protein with androstenedione, brown; protein with biotin, red.
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detected (insets of Figure 6B and 6C), which indicated
the total inhibition of the binding by free testosterone.
Additionally, when the binding sites were preoccupied
with free testosterone, the number of binding events
dropped down to 67 from 183 detected interactions in
the case of sbAvd-1. In case of sbAvd-2 the number of
interactions dropped from of 215 to 21 after addition of
free testosterone.
Differential scanning calorimetry reveals the high
stability of the engineered proteins
The high thermal stability of wtAvd (temperature transi-
tion midpoint (Tm) = 85.5°C) was preserved in the ster-
oid-binding mutants; these proteins showed similar Tm
values compared to wtAvd (sbAvd-1 Tm value of 80.6°C
and sbAvd-2 Tm value of 82.5°C) (Table 1, Additional
file 4). Ligand binding often stabilizes a protein and
raises the Tm value. As expected, the addition of biotin
stabilized wtAvd effectively, increasing the Tm value
almost 40°C. This Tm indicates a very high binding
affinity.
The effect of biotin-binding on the protein stability of
steroid-binding proteins was much smaller than in the
case of wtAvd, thus showing decreased biotin affinity. In
fact, sbAvd-2 showed a negligible increase in Tm in the
presence of biotin (ΔTm = 0.5°C). The presence of tes-
tosterone only slightly increased the Tm values of
sbAvds (ΔTm = 0.6-0.9°C). Actually, a similarly small
increase was detected in the ΔTm value of wtAvd when
testosterone was added. However, because the testoster-
one-binding of wtAvd was not detected in other ana-
lyses (SPR and microplate analysis) the mechanism of
stabilization remains unclear.
Discussion
In the present study, Avd proteins were displayed on the
M13 phage in a monovalent form fused with the C-
terminal region (aa residues 198-406) of the coat protein
pIII. The crucial requirement for the functional display
on phage is successful expression of the protein in E.
coli. As has been earlier reported Avd protein can be
efficiently expressed in a soluble form in E. coli [26].
The close relative of Avd, streptavidin, has been dis-
played on bacterial phages as a pVIII fusion [30,31].
However, to our best knowledge, chicken Avd has not
been previously displayed on phages for screening
purposes.
To evaluate the different modes for Avd display, we
generated constructs expressing pIII fused to Avd and
constructs that expressed free Avd subunits in addition
to the pIII fusions. Based on the expression analysis,
binding properties and selection experiments, the con-
struct that expressed both fusion and free Avd showed
an enhanced assembly of functional, tetrameric Avd on
the phage compared to the Avd-pIII fusion alone (Addi-
tional file 2). However, the construct that expressed
pIII-fused Avd was chosen for use in the selection sys-
tem for the generation of gene libraries because the use
of only one Avd gene in the protein display would
ensure that the selected proteins could be assembled to
homotetramers.
The potential of the developed platform for screening
novel Avd-based receptors was investigated. Five resi-
dues in the loop between b-strands 1 and 2 of Avd were
randomized to generate a population of diverse Avd
genes. The gene population was screened for novel
binding properties using the phage display method [23].
We observed the enrichment of Avd phages binding to
testosterone-coupled BSA. The Avd variant sbAvd-1,
which carried the sequence N12, R13, M14, N15, H16,
was further analyzed and found to bind free testosterone
with an affinity similar to BSA-conjugated testosterone.
Moreover, we detected that the biotin-binding affinity of
sbAvd-1 was not completely diminished; it was still high
enough to inhibit sbAvd-1 from binding to testosterone-
BSA (Table 1, Figures 4 and 5). This finding confirmed
that testosterone occupies the same binding site in Avd
as does biotin. Based on the cross-creativity measure-
ments, sbAvd-1 also binds other steroid hormones, such
as progesterone and DHEAS (Figures 4 and 5).
SbAvd-1 was further engineered to decrease biotin
binding and to improve steroid specificity. From the
Figure 6 Analysis of sbAvd protein-testosterone interaction by
MRFS method (A) A schematic representation of the experimental
assembly used in the analyses. Testosterone was tethered to the
AFM tip using a flexible PEG crosslinker. The steroid-binders sbAvd-1
and sbAvd-2 were covalently bound to the mica surface via a short
homobifunctional spacer. (B) The force-distance cycle of the sbAvd-
1 - testosterone interaction showing an unbinding event. The
typical non-linear shape of the event results from the elastic
properties of the PEG linker. (C) The force-distance cycle showing a
sbAvd-2 - testosterone bond dissociation. Insets in (B) and (C)
represent force-distance cycles in which the protein-testosterone
interaction is inhibited with free testosterone.
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phage display selections, the sbAvd-1-derived protein,
named sbAvd-2, with a mutated loop between b-strands
3 and 4 was captured. This mutant showed similar or
slightly decreased binding affinity towards immobilized
testosterone, whereas the biotin-binding affinity was
clearly decreased (Table 1, Figures 4 and 5). We also
noticed that sbAvd-2 bound more tightly to free testos-
terone than did sbAvd-1 (Figure 5). Significantly, sbAvd-
2 preferred steroids as a ligand over biotin; this finding
is important when considering the applications for bio-
fluids, in which biotin is often present in relatively high
concentrations.
This study and our preliminary results from experi-
ments with a number of different target ligands (Hiltu-
nen S, Riihimäki TA et al., unpublished data) suggest
that Avd-based receptors for various different small
molecules can be tailored. These Avd-based receptors
may be valuable tools for diagnostic use in the future.
Conclusions
The current study provides a promising platform for
the selection of tailored ligand-binders evolved from the
Avd scaffold in the monovalent pIII protein display. The
Avd scaffold has characteristics that are beneficial in
protein engineering, such as high thermal and chemical
stability, simple folding and an optimal structure for
small ligands. Furthermore, Avd can be modified rather
freely without major change in the fold [18]. Novel Avds
that can simultaneously bind multiple ligands could
become next-generation molecular tools for clinical and
diagnostic applications [22,32]. Importantly, novel Avd-
based receptors could be used in applications that
require harsh conditions.
Methods
Construction of phagemid vectors
All of the basic recombinant DNA methods were per-
formed essentially as previously described [33]. Appro-
priate restriction sites were added to the cDNA of the
Avd core sequence [34] by PCR using the primers
Avd_NheI_5’ and Avd_NotI_3’ (Additional file 5). PCR
products were first subcloned into the pCR®2.1-TOPO
plasmid by TOPO TA-cloning (Invitrogen) and the
plasmids were transformed into E. coli TOP10 cells.
Plasmids were isolated from colonies that contained the
inserts based on the blue-white screening. Avd frag-
ments were cut out from the pCR®2.1-TOPO-plasmid
using the NheI and NotI restriction enzymes and ligated
into the phagemid vector (pBluescript SK+ derived
phagemid, Research Center of Finland, Biotechnology,
Espoo, Finland). The cDNA of the Avd was cloned into
the phagemid vector as an N-terminal fusion to the
C-terminal domain (amino acids 198-406) of the minor
phage coat protein III. In the Avd/Avd-pIII constructs,
the coding sequence of the free Avd was subcloned
using the primers Avd_NheI_5’ and Avd_AscI_stop_3’
(Additional file 5). The Avd-pIII expression cassette was
generated by subcloning a fragment amplified from the
primers Avd_SfiI_5’ and Avd_NotI_3’ (Additional file 5).
The nucleotide sequences of the Avd constructs were
verified by sequencing on an ABI PRISM 3100 Genetic
Analyzer (Applied Biosystems) according to the proto-
cols recommended by the manufacturer (ABI PRISM
BigDye Terminator Cycle Sequencing Kit v.1.1, Applied
Biosystems).
Amplification of phage particles
All of the basic phage display methods were performed
essentially as previously described [35]. Phagemid
vectors with the Avd insert were transformed into che-
mically competent E. coli XL1-Blue cells (Stratagene, La
Jolla, CA) with the heat shock method. Phage stocks of
the different Avd display constructs were made from
individual colonies picked from the transformation
plates into super broth (SB) medium supplemented with
the appropriate antibiotics and glucose. The bacterial
cultures were infected with the helper phage (1012 pfu/
ml) VCS-M13 (Stratagene, LaJolla, CA) for amplification
of Avd phages. Phages were PEG precipitated and ana-
lyzed by SDS-PAGE and western blotting following
immunostaining with the polyclonal rabbit a-avd IgG
(University of Oulu, 1:5000) and the monoclonal mouse
anti-pIII IgG (Biosite, Sweden, 1:2000) antibodies.
Functionality test of Avd-displaying phages
The functionality of the Avd phages was tested by pan-
ning the phages on surfaces coated with BSA conjugated
to HABA (HABA-BSA) [36]. As a positive control for
selection, the Avd mutant N118M was also displayed on
the phages. Panning was performed essentially as pre-
viously described [35]. For elution, vigorous shaking in
100 mM hydrochloric acid containing 10 μM D-biotin
(Biochemica, Fluka, 14400) was performed. In total,
three selection rounds were performed. After each
round the integrity of the Avd expression units was ana-
lyzed by restriction enzyme digestions of the phagemid
DNA samples. Importantly, both single and double Avd
and Avd(N118M) construct phages were competed
against each other. Equivalent amounts of phages dis-
playing Avd or Avd(N118M) mutant were mixed and
biopanned. The ratio between constructs was deter-
mined with DNA sequencing.
Construction of Avd L1,2 library
To construct an Avd DNA library, amino acids N12,
D13, L14, G15, and S16 in the loop between beta
strands 1 and 2 (L1,2) were randomized. The libraries
were constructed essentially as previously described
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[35]. A nucleic acid fragment of 105 base pairs was
amplified with the primers Avd_NheI_5’ and Loop 1-2
_R1_3’ (Additional file 5) using wt Avd cDNA as tem-
plate. Parallel to this fragment, a nucleic acid fragment
with 357 base pairs was PCR-amplified with the primers
Loop 1-2_R2_5’ and Avd_NotI_3’ (Additional file 5)
using wt Avd as a template. The PCR strategy is pre-
sented in Additional file 6. The desired amplification
products were separated by agarose gel electrophoresis
and isolated from the gel using the Nucleo Spin Extract
II kit (Macherey-Nagel) according to the manufacturer’s
instructions. PCR products were combined in the sec-
ond amplification step in the presence of the PCR pri-
mers Avd_NheI_5’ and Avd_NotI_3’ (Additional file 5).
This amplification resulted in a DNA fragment of 462
base pairs. The fragment was isolated from the gel and
cut with the restriction enzymes NheI and NotI (Fer-
mentas) followed by purification using the Nucleo Spin
Extract II kit (Macherey-Nagel). Fragments were ligated
into the phagemid vector and the resulting ligation pro-
duct was transformed into electrocompetent cells of the
E. coli strain XL1-Blue (Stratagene) by electroporation.
Transfected bacteria were infected with the VCS-M13
helper phage (Stratagene) and phages were harvested
from the culture and purified with PEG precipitation.
The amount of phage particles was determined by
titration.
Selecting steroid-binders from the Avd L1,2 library
The Avd L1,2 library was panned against the steroid
hormone testosterone. As a negative control, wtAvd-dis-
playing phages were also panned against testosterone.
NUNC immunosorp plates were coated with a testoster-
one-BSA conjugate (Sigma, T-3392, 1 μg). Phages were
preincubated in the BSA-coated wells to prevent non-
specific binding. Three to four selection cycles were
conducted, and the stringency of washing conditions
was increased every panning round to decrease nonspe-
cific binding. In the first panning round wells were
washed three times with phosphate buffered saline con-
taining 0.05% Tween (PBS-Tween) and five times with
phosphate buffered saline (PBS). Phages were eluted by
vigorous shaking for 10 minutes in 100 mM hydrochlo-
ric acid containing 10 μM D-biotin (Biochemica, Fluka,
14400). Biotin was used for elution because it was prob-
able that after randomization of the loop L1,2 the result-
ing Avd would still have a rather high affinity towards
biotin. In the final panning round 10 μM testosterone
(Steraloids Inc., USA) was used in addition to 100 mM
hydrochloric acid for elution. The eluted phage solutions
were neutralized with 2 M Tris. Eluted phages were
used to infect E. coli XL1-Blue cells and aliquots of the
infected bacteria were plated to quantify the amount of
eluted phages. Phages were amplified and purified as
described earlier. Precipitated phages were then used for
the next round of selection. After every panning round,
results were verified by sequencing (20 sequences), and
the number of phage particles was determined by phage
titration.
Generation and screening of the SbAvd-1 L3,4 library
An SbAvd-1-derived DNA library was constructed and
ligated into the phagemid as described above. In the
library amino acids T35, A36, V37, and T38 in the loop
between beta strands 3 and 4 (L3,4) were randomized;
thus, in the construction of the library the primers
Avd_NheI_5’ and 3_4R_1_3’ and primers 3_4R_2_5’ and
Avd_NotI_3’ (Additional file 5) were used in the PCR.
SbAvd-1 cDNA was used as a template. Ligated phage-
mid was transformed into electrocompetent cells of E.
coli strain XL1-Blue (Stratagene) by electroporation.
Transfected bacteria were infected with the VCS-M13
helper phage (Stratagene) and phages were harvested
from the culture and purified with PEG precipitation.
The amount of phage particles was determined by
titration.
The sbAvd-1 L3,4 library was biopanned against the
steroid hormone testosterone similarly as described
above, with some exceptions. NUNC immunosorp plates
were coated with a testosterone-BSA conjugate (Sigma,
T-3392, 200 ng). Phages were preincubated in BSA-
coated wells before the panning procedure. Four selec-
tion cycles were performed. Phages were eluted by vig-
orous shaking for 10 minutes in 100 mM hydrochloric
acid containing 35 μM testosterone (Steraloid Inc.,
USA). After each panning round, results were verified
by sequencing (20 sequences), and the number of phage
particles was determined by phage titration. Addition-
ally, every panning round was screened for binders by
anti-M13 as previously described [37]. For the ELISA,
(NUNC) immunosorp plates were coated with a testos-
terone-BSA conjugate (Sigma, T-3392, 1 μg), wells were
blocked with 5% milk solution, and detection was per-
formed with Anti-M13/HRP (GE Healthcare) and read
with a microplate reader (Bio-Rad 680 XR).
Production and purification of Avd mutants
For biochemical analyses, the proteins were produced in
E. coli strain BL21-AI (Invitrogen) using expression vec-
tor pET101/D (Invitrogen) [26]. After sonication (Sonics
& Materials Vibra Cell™) and DNaseI (New England
Bio Labs) treatment of E. coli cells, the purification of
the proteins was conducted using Ni-NTA affinity chro-
matography according to the instructions of the manu-
facturer (QIAGEN).
The oligomeric state of the proteins was assayed with
fast protein liquid chromatography (FPLC) gel-filtration
using an ÄKTApurifier™ HPLC equipped with a
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Superdex 200 10/300 GL column (Tricorn, Amersham
Biosciences, GE Healthcare). The column was calibrated
using the gel-filtration mixture (thyroglobulin, g-globu-
lin, ovalbumin, myoglobin, and vitamin B12; Bio-Rad
Laboratories) as a molecular-mass standard. Sodium
phosphate buffer (20 mM, pH 7.4) with 1M NaCl and,
20 mM imidazole was used as the liquid phase. Protein
samples of 90-193 μg in a volume of 500 μl were used
in the analysis.
DSC measurements of wtAvd and steroid-binding Avds
Proteins (0.225 mg/ml) were analyzed in sodium
phosphate buffer (20 mM, pH 7.4), containing 20 mM
imidazole and 1 M NaCl. D-biotin (Biochemica, Fluka,
14400) and testosterone (Steraloids Inc., USA) were
diluted with the measurement buffer to a final concen-
tration of 50 μM. All solutions were degassed prior to
measurements to avoid air bubbles. An automated
capillary VP-DSC instrument (GE Healtcare, MicroCal,
Northampton, USA) was used to measure the stability
of the proteins with or without ligands. During the
measurement, protein samples were heated from 20°C
to 130°C at a scanning rate of 120°C/h. Feedback
mode was set to low and the filler period was 8 s.
Temperature transition midpoints (Tm) were recorded
from the highest peaks and the calorimetric heat
changes (ΔH) were calculated using the MicroCal
Origin 7 software (GE Healtcare, MicroCal, Northamp-
ton, USA).
Determination of ligand-binding specificity of Avd forms
by microplate assay
MaxiSorp F96 microplate wells (NUNC) were coated
with 500 ng of conjugated ligand (HSA-conjugated pro-
gesterone, hydrocortisone, testosterone, and cholic acid
(Technical Research Center of Finland, Espoo, Finland);
or BSA-conjugated testosterone (A6958-000, Steraloids
Inc., USA), and biotin (Jenni Leppiniemi, University of
Tampere, Finland)), and with 500 ng of the carrier pro-
teins HSA and BSA (A7906, Sigma) in 100 μl of PBS for
2 hours 37°C. Carrier proteins were used as negative
controls. Plates were washed three times with PBS-
Tween, blocked with 0.5% BSA-PBS for 30 min, and
then washed again. Proteins (0.9 μg/ml) in sodium phos-
phate buffer (20 mM, pH 7.4) with 1M NaCl and 20
mM imidazole, were added to the wells and incubated
for 1 h. A portion of wtAvd (Belovo, Bastogne, Belgium),
sbAvd-1 and sbAvd-2 was preincubated with 10 μM D-
biotin (Biochemica, Fluka, 14400). Bound Avd was
detected by rabbit a-avd IgG (University of Oulu) and
with alkaline phosphatase conjugated goat anti-rabbit
IgG (A3937, Sigma). After adding the phosphatase
substrate solution (1 mg/ml pNPP (S0942, Sigma) in 1
M diethanolamine pH 9.8, with 0.5 mM MgCl2), the
plates were read after 15 minutes at A405 with a micro-
plate reader (Bio-Rad 680 XR).
Biosensor analyses of steroid-binding Avds
A BIAcore X optical biosensor (Biacore, Uppsala, Swe-
den) was used for the analysis of binding kinetics. Tes-
tosterone-BSA was coupled to the carboxymethylated
dextran layer of a sensor chip using standard amine
coupling chemistry (1000 RU, 40 μl/min flow rate).
Samples of sbAvd-1, and sbAvd-2 were diluted in 50
mM sodium phosphate containing 1 M NaCl, and the
same buffer was used in the measurements. The binding
of the sbAvd-1 and sbAvd-2 samples on testosterone-
BSA coated chips was measured and the kinetic con-
stants were determined from the measurements per-
formed with different protein concentrations using the
BiaEvaluation software according to the manufacturer’s
instructions. WtAvd was used as a negative control.
The binding of steroid-binding proteins to the testos-
terone-BSA surface was competed with free steroid hor-
mone molecules (testosterone, DHEAS,
androstenedione, estradiol, and DHT (Steraloids Inc.,
USA)) and free biotin (Biochemica, Fluka, 14400) to
evaluate the specificity of binding. Additionally, steroid-
binding was more closely detected by measuring the
binding in the presence of varying concentrations (0.75
μM-50 μM) of inhibiting testosterone.
For the determination of biotin-binding kinetics, a
sensor chip was prepared as follows: diaminoethylene
was first attached to the surface using a mixture con-
taining 0.2 M 1-ethyl-3-(3-dimethylaminopropyl) carbo-
diimide hydrochloride (EDC) and 0.05 M N-
hydroxysuccinimide (NHS) in water. Second, to intro-
duce amino groups to the surface, 1 M ethylenediamine
(Fluka 03550) in water was applied. Finally, 5 mM biotin
N-succinimidyl ester (Biochemica, Fluka, 14405) in 50%
DMSO was injected on the surface (40 μl/min flow rate,
~130 RU; please note that the determination of the
bound mass is not very accurate in case of small mole-
cules because the immobilization can change the physi-
cochemical properties of the surface).
Molecular Recognition Force Spectroscopy experiments
Molecular recognition force spectroscopy (MRFS) was
used to study the interaction of the produced proteins
with testosterone and biotin. Steroid-binding proteins
were covalently bound to modified mica sheets via
lysines as previously described [38]. Testosterone was
coupled to the AFM tip via the heterobifunctional
Fmoc-PEG-NHS crosslinker as previously described
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[28], resulting in a covalent attachment of testosterone
via a flexible spacer (Figure 6A).
All MRFS experiments were performed on a Pico SPM
I (Agilent Technologies, Santa Clara, CA). All modified
cantilevers used had nominal spring constants between
10-30 pN/nm (Veeco Instruments, Santa Barbara, CA).
The effective spring constants of the cantilevers were
determined by the thermal noise method [39,40]. Force-
distance cycles were completed using a z-range of 200
and 300 nm. Sweep durations were adjusted between
0.25 and 4 s. During one data set of 1000 force-distance
curves, the lateral tip position was changed (a few hun-
dred nm) about every 100 curves to ensure that the
binding events were statistically reasonable. The specifi-
city of the binding was proved by adding free testoster-
one (200 nM) into the measuring solution and
incubating for approximately 1 h to block the ligand-
binding sites of the proteins.
Additional material
Additional file 1: Structural comparison of Avd-BTN and Avd-HABA
complexes. 3D-structures of Avd complexed with biotin (A) and HABA
(B). These two ligands have different hydrogen bonding interactions with
the amino acids at the binding site. (A) Hydrogen bonds formed
between the ureido ring of biotin and Avd are shown here as dashed
green lines. (X-ray crystallographic structure (PDB 2AVI)) [41]. (B) A
significant difference between biotin and HABA binding to Avd is seen
in the interaction of the ligand with asparagine 118. Although other Avd
key residues interacting with the BTN ureido ring also interact with
HABA, there is no hydrogen bonding partner for N118 in HABA. Again,
hydrogen bonds formed between the carboxyl group of HABA and Avd
are shown as dashed green lines. The loop between b-strands 3 and 4
was not resolved in the avd-HABA -complex (coordinates kindly provided
by Prof. Oded Livnah). The figure was made with the VMD program [42].
Additional file 2: Sequencing results and input from the control
selections. The percentage of wt Avd and Avd(N118M) mutant
sequences after sequencing analysis from the different rounds of HABA
selection. The amount of input phages is shown as colony forming units
(cfu) per milliliter of culture.
Additional file 3: Gel-filtration chromatograms of sbAvd-1 and
sbAvd-2 proteins. The chromatograms of steroid-binding proteins
determined at wavelength of 280 nm by gel-filtration. Besides the main
peak, there is also a small peak of oligomeric form of the protein in the
chromatogram of sbAvd-1 protein (gray curve). It is a typically
observation also in the case of wtAvd [26]. The chromatogram of sbAvd-
2 protein is shown with black curve. The tetrameric form of the protein
is dominant in both samples.
Additional file 4: The effect of ligand-binding to the stability of
wtAvd, sbAvd-1 and sbAvd-2 proteins. DSC thermograms were
obtained from the protein sample (0.225 mg/ml) by scanning
temperature range of 20°C to 130°C with heating rate of 120°C/min. The
analysis was conducted in the absence and presence of ligands (50 μM).
Additional file 5: The cloning primers used in the study. The
restriction enzyme cleavage sites are indicated in italics.
Additional file 6: A schematic presentation of the construction
strategy of the Avd L1,2 library. for 1-2 loop library a nucleic acid
fragment of 105 base pairs was amplified (Step 1, A) with the primers
Avd_NheI_5’ and Loop 1-2 _R1_3’ (schematically referred in the figure as
Avd_mutant_3’) using wtAvd cDNA as a template. Parallel to this, a
nucleic acid fragment with 357 base pairs, was PCR-amplified (Step 1, B)
with the primers Loop 1-2_R2_5’ (schematically referred in the figure as
Avd_combine_5’) and Avd_NotI_3’, also using wtAvd as a template.
Amplified fragments were combined in a second amplification step in
the presence of PCR primers Avd_NheI_5’ and Avd_NotI_3’, wherein a
DNA fragment of 462 base pairs was obtained.
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